Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.39 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.39 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.39 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21527802 | 0.80 | KDM4E (0.34) | — | |
| SCHEMBL21798590 | 0.77 | KMT2A (0.49) | CA2CA9 | |
| SCHEMBL21527753 | 0.77 | HPGD (0.41) | CA2CA9 | |
| SCHEMBL17097221 | 0.72 | CA9 (0.58) | CA2CA9ABCC9ABCC8KCNJ11 | |
| SCHEMBL22226932 | 0.72 | CA9 (0.58) | CA2CA9ABCC9ABCC8KCNJ11 | |
| SCHEMBL13534170 | 0.72 | CA9 (0.58) | CA2CA9ABCC9ABCC8KCNJ11 | |
| SCHEMBL18152702 | 0.70 | BRD4 (0.38) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL20172048 | 0.69 | CA9 (0.62) | CA2CA9ABCC9ABCC8KCNJ11 | |
| SCHEMBL2616776 | 0.67 | CA9 (0.59) | CA2CA9ABCC9ABCC8KCNJ11 | |
| SCHEMBL8546709 | 0.66 | CA9 (0.53) | CA2CA9ABCC9ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683289-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683289-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190337935-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683289-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, AIFM1, BCL2 | CA2 4211/4885CA9 4642/4885ABCC9 2330/4885 |
| US-20190337935-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, AIFM1, BCL2 | CA2 4211/4885CA9 4642/4885ABCC9 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.